Phenglutarimide hydrochloride

General description L -&#945:-Phosphatidylethanolamine from egg yolk has high unsaturated fatty acid content and elicits radical-scavenging activity. L -&#945:-Phosphatidylethanolamine (PE) is a membrane phospholipid and is interconverted to

Application 1,2-Dipalmitoyl- sn -glycero-3-phosphoethanolamine is used in model membrane . Biochem/physiol Actions 1,2-Dipalmitoyl- sn -glycero-3-phosphoethanolamine is a phospholipid, a lipid component in cell membrane .

General DescriptionL-α-Phosphatidylethanolamine from egg yolk has high unsaturated fatty acid content and elicits radical-scavenging activity. L-α-Phosphatidylethanolamine (PE) is a membrane phospholipid and is interconverted to phosphotidylserine

General DescriptionL-α-Phosphatidylethanolamine from egg yolk has high unsaturated fatty acid content and elicits radical-scavenging activity. L-α-Phosphatidylethanolamine (PE) is a membrane phospholipid and is interconverted to phosphotidylserine

L-PHENLalaninamide hydroCHLRIDE 97% 100g

L-Phenylalaninamide hydroCHLRIDE 97% 25g

Ligustilide is a phthalide derivative that has been shown to have broad applications in the study and treatment of cardiovascular diseases and ischemic brain injury.

Ligustilide is a phthalide derivative that has been shown to have broad applications in the study and treatment of cardiovascular diseases and ischemic brain injury.

Lotilaner is a parasiticide , acts as a potent non-competitive antagonist of insects GABACl receptors , with an IC 50 of 23.84 nM for Drosophila melanogaster GABA receptor . No effect on a dog GABAA receptorIn VitroLotilaner shows IC 50 s of 38.25 ±

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).In VivoLp-PLA2-IN-3 (3 mg/kg: p.o.) treatment shows the C max , AUC 0-24h ,

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).In VivoLp-PLA2-IN-3 (3 mg/kg: p.o.) treatment shows the C max , AUC 0-24h ,

Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).In VivoLp-PLA2-IN-3 (3 mg/kg: p.o.) treatment shows the C max , AUC 0-24h ,